Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients

Metformin is used widely in the treatment of type 2 diabetes. It has off-label indications for use in the prevention of diabetes and in hyperinsulinar obesity. In medical practices, the implementation of metformin for these off-label indications is variable, often at the level of the provider. Multiple retrospective investigations have also shown a clinical benefit in men with prostate cancer who are incidentally treated with metformin. This pragmatic study will test the feasibility of enrolling patients who have glucose intolerance (as defined by HbA1c of 5.7-6.4%) and/or who have increased

Trial Details

NCT ID
NCT05515978
Phase
EARLY_PHASE1
Sponsor
University of Colorado, Denver
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Metformin
  • Lifestyle Modification
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Colorado Springs, Colorado, United States|38.83388,-104.82136
  • Denver, Colorado, United States|39.73915,-104.9847
  • Fort Collins, Colorado, United States|40.58526,-105.08442

Key Eligibility Criteria

  • In order to be eligible to participate in this study, an individual must meet all of the following criteria. The patients will be screening for eli…
  • Provision to sign and date the consent form in MHC or otherwise via Epic.
  • Subjects must have an MHC Account to participate in the study
  • Be a male aged ≥18 years of age on day of signing the informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →